The role of α-zearalanol in reversing bone loss induced by ovarian hormone deficiency in rats

To assess the ability of α-zearalanol (α-ZAL) to prevent bone loss in an ovariectomized (OVX) rat model of osteoporosis, α-ZAL was administered intragastrically to rats. After 35 days, the total body bone mineral density (BMD) was assessed in all rats. All sections were processed for immunohistochem...

Full description

Saved in:
Bibliographic Details
Published in:Journal of bone and mineral metabolism 2012-03, Vol.30 (2), p.136-143
Main Authors: Zong, Shaohui, Wei, Bo, Xiong, Chunxiang, Zhao, Yuxi, Zeng, Gaofeng
Format: Article
Language:English
Subjects:
Acid Phosphatase - metabolism
Alkaline Phosphatase - metabolism
Animals
Biological and medical sciences
Body Weight - drug effects
Bone Density - drug effects
Bone Morphogenetic Proteins - metabolism
Bone Resorption - drug therapy
Bone Resorption - enzymology
Bone Resorption - pathology
Diseases of the osteoarticular system
Estrogens - deficiency
Female
Fibroblast Growth Factor 2 - metabolism
Indexing in process
Isoenzymes - metabolism
Medical sciences
Medicine
Medicine & Public Health
Metabolic Diseases
Original Article
Orthopedics
Osteocalcin - metabolism
Osteoporosis. Osteomalacia. Paget disease
Ovariectomy
Ovary - drug effects
Ovary - metabolism
Ovary - surgery
Progesterone - deficiency
Rats
Rats, Sprague-Dawley
Staining and Labeling
Tartrate-Resistant Acid Phosphatase
Tibia - drug effects
Tibia - enzymology
Tibia - pathology
Tumor Necrosis Factor-alpha - metabolism
Zeranol - pharmacology
Zeranol - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess the ability of α-zearalanol (α-ZAL) to prevent bone loss in an ovariectomized (OVX) rat model of osteoporosis, α-ZAL was administered intragastrically to rats. After 35 days, the total body bone mineral density (BMD) was assessed in all rats. All sections were processed for immunohistochemistry and hematoxylin and eosin staining. One-way ANOVA and an LSD multiple-range test were used to determine the significant differences between groups. BMD was lower in the OVX and OVX + α-ZAL high-dose (OVX + High) groups compared to the sham-operated (Sham), OVX + 17β-ethinylestradiol (OVX + E 2 ), OVX + α-ZAL medium-dose (OVX + Medium) and OVX + α-ZAL low-dose (OVX + Low) groups ( P  
ISSN:0914-8779
1435-5604
DOI:10.1007/s00774-011-0302-8